Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19095542 | 0.86 | ESR2 (0.49) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL2502784 | 0.85 | — | — | |
| SCHEMBL17298097 | 0.81 | ESR2 (0.44) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL905258 | 0.81 | ESR2 (0.54) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL1668850 | 0.81 | ESR2 (0.54) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL25313837 | 0.79 | ESR2 (0.53) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3812522 | 0.79 | ESR2 (0.53) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL6093145 | 0.79 | ESR2 (0.53) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL25311256 | 0.79 | ESR2 (0.53) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL4687838 | 0.79 | ESR2 (0.53) | ESR2RECQLSMN1; SMN2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561552-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197978-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | ESR2 84/4885RECQL 4404/4885SMN1; SMN2 3341/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | ESR2 3700/4885RECQL 287/4885SMN1; SMN2 1976/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | ESR2 2622/4885RECQL 676/4885SMN1; SMN2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.